Skip to main content
Signal8

CERO THERAPEUTICS HOLDINGS, INC. (CERO) Form 10-Q — Nov 13, 2026

$CEROForm 10-QFiled Nov 13, 2026, 4:05 PM ET0001213900-26-119677Original filing

CERo Therapeutics Holdings reported a going-concern warning in its Q3 2026 10-Q, holding just $650,681 in cash against a working capital deficit of approximately $19.3 million and a stockholders' deficit of $18.8 million. Management stated that available cash will not fund operations for one year, and the company used $8.1 million of cash in operations over the first nine months of 2026. The quarter's reported net income of $4.0 million was driven entirely by non-cash items, including a $3.8 million gain on debt extinguishment and a $3.7 million gain from revaluing preferred stock liabilities, not by operations.

Key figures

Total Debt
8126403
Cash Position
650681
Shares Outstanding
83309742
Q3 basic eps
0.06
Q3 net income
4019112
Reverse splits
1-for-100 (Jan 2025) and 1-for-20 (Jun 2025)
Keystone commitment
25000000
Working capital deficit
approximately $19.3 million
Convertible notes proceeds
4485200
Consolidated note principal
5666109
Gain on debt extinguishment
3801413
Gain on preferred stock liabilities 9m
10335126

AI analysis

Red flags8 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.